|
|
 |
|
 |
|
|
|
|
Title:
|
A Phase II Trial of SCH 727965 (NSC 747135) in Patients with Stage IV Melanoma - IRB #09-080A
|
|
Treatments:
|
SCH 727965
|
|
Disease Site:
|
Melanoma
|
|
Disease SubSite:
|
|
|
Drug Provided:
|
SCH 727965
|
|
Comments:
|
|
|
Eligibility:
|
Biopsy-confirmed malignant melanoma. Stage IV disease. Cutaneous or mucosal origin. Melanoma of unknown primary allowed. No ocular melanoma. Measurable or non-measurable disease . No prior or concurrent brain metastases as confirmed by CT scan or MRI. Prior/Concurrent Therapy: No prior therapy with a cyclin-dependent kinase inhibitor. At least 14 days since prior radiotherapy. At least 28 days since prior systemic chemotherapy. At least 28 days since prior adjuvant systemic therapy. At least 28 days since prior surgery. No more than 1 prior systemic therapy regimen (chemotherapy, biologic/immunotherapy, hormonal therapy, or a combination regimen) for stage IV melanoma and any side effects must have resolved to =< grade 1. Any number of prior adjuvant systemic therapy regimens allowed, including interferon alfa-2b, GM-CSF, chemotherapy, and chemobiotherapy. Therapy for stage IV resected free-of-disease will be considered adjuvant therapy.
|
|
Participating Sites:
|
Adventist Medical Center, Northwest Cancer Specialists, Providence Milwaukie Hospital, Providence Portland Medical Center, Providence St. Vincent Medical Center, Southwest Washington Medical Center
|
|
|
|
|
 |
|
 |
|
|
|